Update on current research into haploidentical hematopoietic stem cell transplantation

被引：21

作者：

Sun, Yu-Qian ^{[1
,2
]}

Chang, Ying-Jun ^{[1
,2
]}

Huang, Xiao-Jun ^{[1
,2
,3
]}

机构：

[1] Peking Univ, Inst Hematol, Peoples Hosp, Beijing, Peoples R China

[2] Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China

[3] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China

来源：

EXPERT REVIEW OF HEMATOLOGY | 2018年 / 11卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Baltimore protocol; Beijing protocol; graft-versus-host disease; haploidentical stem cell transplantation; poor graft function; relapse; severe aplastic anemia; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ACUTE MYELOID-LEUKEMIA; SEVERE APLASTIC-ANEMIA; REGULATORY T-CELLS; DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; UNRELATED DONOR TRANSPLANTATION; COLONY-STIMULATING FACTOR; UMBILICAL-CORD BLOOD;

D O I：

10.1080/17474086.2018.1447379

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Haploidentical stem cell transplantation (Haplo-SCT) is currently a suitable alternative worldwide for patients with hematological diseases, who lack human leukocyte antigen (HLA)-matched siblings or unrelated donors.Areas covered: This review summarizes the advancements in Haplo-SCT in recent years, primarily focusing on the global trends of haploidentical allograft, the comparison of outcomes between Haplo-SCT and other transplantation modalities, strategies for improving clinical outcomes, including donor selection, hematopoietic reconstitution promotion, and graft-versus-host disease, and relapse prevention/management, as well as the expanded indications of Haplo-SCT, such as severe aplastic anemia, myeloma and lymphoma.Expert commentary: Haploidentical allografts, including granulocyte colony-stimulating factor-based protocol and a post-transplant cyclophosphamide-based protocol, have been the mainstream strategy for Haplo-SCT. However, there are many unanswered questions in this field.

引用

页码：273 / 284

页数：12

共 139 条

[1] γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes [J].

Airoldi, Irma ;

Bertaina, Alice ;

Prigione, Ignazia ;

Zorzoli, Alessia ;

Pagliara, Daria ;

Cocco, Claudia ;

Meazza, Raffaella ;

Loiacono, Fabrizio ;

Lucarelli, Barbarella ;

Bernardo, Maria Ester ;

Barbarito, Giulia ;

Pende, Daniela ;

Moretta, Alessandro ;

Pistoia, Vito ;

Moretta, Lorenzo ;

Locatelli, Franco .

BLOOD, 2015, 125 (15) :2349-2358

[2] Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors [J].

Anurathapan, U. ;

Hongeng, S. ;

Pakakasama, S. ;

Sirachainan, N. ;

Songdej, D. ;

Chuansumrit, A. ;

Charoenkwan, P. ;

Jetsrisuparb, A. ;

Sanpakit, K. ;

Rujkijyanont, P. ;

Meekaewkunchorn, A. ;

Lektrakul, Y. ;

Iamsirirak, P. ;

Surapolchai, P. ;

Satayasai, W. ;

Sirireung, S. ;

Sruamsiri, R. ;

Wahidiyat, P. A. ;

Ungkanont, A. ;

Issaragrisil, S. ;

Andersson, B. S. .

BONE MARROW TRANSPLANTATION, 2016, 51 (06) :813-818

[3] Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States [J].

Apperley, Jane ;

Niederwieser, Dietger ;

Huang, Xiao-jun ;

Nagler, Arnon ;

Fuchs, Ephraim ;

Szer, Jeff ;

Kodera, Yoshihisa .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (01) :23-26

[4] Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].

Aversa, F ;

Tabilio, A ;

Velardi, A ;

Cunningham, I ;

Terenzi, A ;

Falzetti, F ;

Ruggeri, L ;

Barbabietola, G ;

Aristei, C ;

Latini, P ;

Reisner, Y ;

Martelli, MF .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193

[5] Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse [J].

Aversa, F ;

Terenzi, A ;

Tabilio, A ;

Falzetti, F ;

Carotti, A ;

Ballanti, S ;

Felicini, R ;

Falcinelli, F ;

Velardi, A ;

Ruggeri, L ;

Aloisi, T ;

Saab, JP ;

Santucci, A ;

Perruccio, K ;

Martelli, MP ;

Mecucci, C ;

Reisner, Y ;

Martelli, MF .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3447-3454

[6] Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update [J].

Bacigalupo, A. ;

Dominietto, A. ;

Ghiso, A. ;

Di Grazia, C. ;

Lamparelli, T. ;

Gualandi, F. ;

Bregante, S. ;

Van Lint, M. T. ;

Geroldi, S. ;

Luchetti, S. ;

Grasso, R. ;

Pozzi, S. ;

Colombo, N. ;

Tedone, E. ;

Varaldo, R. ;

Raiola, A. M. .

BONE MARROW TRANSPLANTATION, 2015, 50 :S37-S39

[7] Umbilical cord blood transplantation: the first 25 years and beyond [J].

Ballen, Karen K. ;

Gluckman, Eliane ;

Broxmeyer, Hal E. .

BLOOD, 2013, 122 (04) :491-498

[8]

Barnes K M, 1991, MLO Med Lab Obs, V23, P59

[9]

Barnes KM, 1991, MLO MED LAB OBS, V23, P59

[10] T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation [J].

Bashey, Asad ;

Zhang, Xu ;

Sizemore, Connie A. ;

Manion, Karen ;

Brown, Stacey ;

Holland, H. Kent ;

Morris, Lawrence E. ;

Solomon, Scott R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) :1310-1316

← 1 2 3 4 5 6 7 8 9 10 →